AstraZeneca non-exec takes more shares

Jean-Phillippe Courtois, a non-executive director at AstraZeneca, has spent nearly £50,000 upping his stake in the drug giant.

He bought 2,135 shares for 2,299p each and now has 2,635.

News of his purchase came on the same day AstraZeneca was celebrating a favourable decision from US regulators regarding its new drug application for diabetes treatment ONGLYZA.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee decided that the data supporting the drug application for ONGLYZA were sufficient to discount unacceptable cardiovascular risk.

Courtois, who is also the President of software company Microsoft's non-US operations, was appointed to Astra's board on February 18.

Top Director Buys

Value: £99,120

Value: £99,120

Value: £98,000

Value: £49,084

Value: £25,002

Value: £25,000

Value: £25,000

Value: £14,600

Value: £13,411

Value: £12,250

Top Director Sells

Value: £2,800,000

Value: £321,247

Value: £10,040